Drugs in Context
LightNews LightNews
drugsincontext.bsky.social
Drugs in Context
@drugsincontext.bsky.social
82 followers 650 following 49 posts
Drugs in Context publishes high-quality, peer-reviewed articles covering the latest evidence and innovations in drug treatment across all therapeutic areas.
JCR 2025 JIF 2.8
WoS ESCI, PubMed, Scopus, DOAJ
https://www.drugsincontext.com/
Posts Replies Media Videos
Pinned
drugsincontext.bsky.social
Drugs in Context @drugsincontext.bsky.social · Jun 19
🎉 Exciting News! 🎉

We are thrilled to announce that @drugsincontext.bsky.social has received its very first Clarivate JIF (2024 JIF 2.8)!

For info, please visit our webpage (www.drugsincontext.com) or email us ([email protected])

#MedKy #PharmSky #ImpactFactor #ClarivateJCR2025
Welcome to Drugs in Context - Drugs in Context
Drugs in Context is indexed in Clarivate JCR with a 2024 JIF of 2.8 Clarivate ESCI, is a member of the Directory of Open Access Journals, and is listed on
www.drugsincontext.com
drugsincontext.bsky.social
💊 Emerging concepts in HIV pre-exposure prophylaxis: focus on twice-yearly lenacapavir

Anderson

Full article here: www.drugsincontext.com/emerging-con...

#HIVPrevention #PrEP #Lenacapavir #PublicHealth #ClinicalTrials #InfectiousDiseases #HealthEquity #Pharmacology @medsky.social @me.pharmsky.app
February 5, 2026 at 3:41 PM
drugsincontext.bsky.social
💊 Ustekinumab-associated morphoea: systematic review of the literature and a real-world case

Sousa et al.

Read the full article here: www.drugsincontext.com/ustekinumab-...

#Dermatology #Immunology #Pharmacovigilance #Ustekinumab #Biologics @medsky.social @me.pharmsky.app
February 3, 2026 at 4:04 PM
drugsincontext.bsky.social
💊 The convergent pathway of obstructive lung disease: the disease-modifying potential of dipeptidyl peptidase 1 inhibition in COPD, asthma and bronchiectasis overlap
Menzella et al.
#respiratorymedicine #ClinicalTrials #COPD @medky.bsky.social @me.pharmsky.app
www.drugsincontext.com/the-converge...
January 29, 2026 at 3:26 PM
drugsincontext.bsky.social
💊Optimizing care and quality indicators in the management of patients with acute ischaemic heart disease and atherothrombotic stroke: measuring to improve

González-Juanatey et al.
#cardiology #HealthcareQuality #PublicHealth @me.pharmsky.app @medsky.social

www.drugsincontext.com/optimizing-c...
January 27, 2026 at 11:03 AM
drugsincontext.bsky.social
💊 Role of a topical hydrogel (Dermatix® wound care gel) in acute and chronic wound management: a case series of real-world experiences and expert opinion from Asia

Lee et al.

#WoundCare #Hydrogel #Dermatology @medsky.social @me.pharmsky.app

www.drugsincontext.com/role-of-a-to...
January 21, 2026 at 7:04 AM
drugsincontext.bsky.social
💊New article in @drugsincontext.bsky.social

Apremilast in osteoarthritis: exploring its therapeutic mechanisms

Rafiei et al.

www.drugsincontext.com/apremilast-i...

@medsky.social @me.pharmsky.app #osteoarthritis #smallmoleculeinhibitors #rheumatology
December 29, 2025 at 11:37 AM
drugsincontext.bsky.social
Sphingosine-1-phosphate receptor modulators in ulcerative colitis – a narrative review of current evidence and practical considerations
Kuriakose Kuzhiyanjal et al.
@ncaresearchnhs.bsky.social @medsky.social @me.pharmsky.app #Gastroenterology #UlcerativeColitis
www.drugsincontext.com/sphingosine-...
Sphingosine-1-phosphate receptor modulators in ulcerative colitis – a narrative review of current evidence and practical considerations - Drugs in Context
This comprehensive review of Sphingosine-1-phosphate receptor modulators explores their mechanism of action, key clinical trial data, real-world insights, and an overview of their safety, including co...
www.drugsincontext.com
December 19, 2025 at 8:30 AM
drugsincontext.bsky.social
Adjuvant abemaciclib in early-stage breast cancer: hypothesis-generating safety observations from a real-world cohort study

Sottotetti et al.

www.drugsincontext.com/adjuvant-abe...

#MedSky #PharmSky #BreastCancer #Oncology #Abemaciclib #PersonalizedMedicine @medsky.social @me.pharmsky.app
Adjuvant abemaciclib in early-stage breast cancer: hypothesis-generating safety observations from a real-world cohort study - Drugs in Context
This study aims to enhance comprehension of the clinical efficacy and safety of adjuvant abemaciclib in older women in a real-world setting compared with younger women.
www.drugsincontext.com
December 11, 2025 at 3:20 PM
drugsincontext.bsky.social
💊 Effectiveness of the antihistamine and anti-PAF effects of rupatadine in allergic diseases: off-label use in a case series study
Aguiar et al.
#Immunology #Allergology #Dermatology #Pediatrics #Rupatadine @medsky.social @topics.medsky.social @me.pharmsky.app
www.drugsincontext.com/effectivenes...
medsky.social
December 10, 2025 at 7:43 AM
drugsincontext.bsky.social
Holistic care in mild upper respiratory tract infections (MURTIs): an approach to individualized care management

Smith et al.

#drugsincontext #respiratorymedicine #urti #murti #pharmacology #holisticcare #MedSky #PharmSky @medsky.social @me.pharmsky.app

www.drugsincontext.com/holistic-car...
December 4, 2025 at 5:36 PM
drugsincontext.bsky.social
💊 Deferiprone therapy improves the oxidative status of LDL in patients with β-thalassaemia/HbE

Tran et al.

#drugsincontext #hematology #ldl #lipidology #pharmacology #MedSky #PharmSky @medsky.social @me.pharmsky.app

www.drugsincontext.com/deferiprone-...
Deferiprone therapy improves the oxidative status of LDL in patients with β-thalassaemia/HbE - Drugs in Context
This study assesses the protective effect of deferiprone on the oxidative status of low-density lipoproteins in patients with β-thalassaemia/haemoglobin E.
www.drugsincontext.com
December 3, 2025 at 2:51 PM
drugsincontext.bsky.social
💊 Biologics and small molecules for psoriasis: current and future progress

Potestio et al.

@drugsincontext.bsky.social #dermatology #psoriasis #biologics #smallmolecules #pharmacology #MedSky #PharmSky

@medsky.social @me.pharmsky.app

www.drugsincontext.com/biologics-an...
November 20, 2025 at 4:10 PM
drugsincontext.bsky.social
💊N-acetylcysteine in paediatrics: a review of efficacy, safety and dosing strategies in respiratory care

Benedetti & Santus

#MedSky #PharmSky #Pediatrics #RespiratoryHealth #EvidenceBasedMedicine

@drugsincontext.bsky.social @medsky.social @me.pharmsky.app

www.drugsincontext.com/n-acetylcyst...
November 13, 2025 at 7:22 PM
drugsincontext.bsky.social
💊 Multimodal treatment of pineal metastasis from oesophageal adenocarcinoma

Rifaldi et al.

@drugsincontext.bsky.social #oncology #neurology #gastroenterology #CaseReport #metastasis #tumors #MedSky #PharmSky @medsky.social @me.pharmsky.app

www.drugsincontext.com/multimodal-t...
October 31, 2025 at 5:01 PM
drugsincontext.bsky.social
💊Place in therapy of key treatments for platinum-sensitive, relapsed, extensive-stage small cell lung cancer with a focus on lurbinectedin: a narrative review with case studies

Shunyakov et al.

@drugsincontext.bsky.social #sclc #oncology
@me.pharmsky.app
www.drugsincontext.com/place-in-the...
October 29, 2025 at 12:16 PM
drugsincontext.bsky.social
💊 JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review

Henriques dos Santos et al.

@drugsincontext.bsky.social #dermatology #JAKinhibitors #biologics #MedSky #PharmSky

www.drugsincontext.com/jak-inhibito...
JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review - Drugs in Context
This narrative review evaluates current evidence on the efficacy and safety of JAK inhibitors in the treatment of palmoplantar pustulosis.
www.drugsincontext.com
October 22, 2025 at 10:15 AM
drugsincontext.bsky.social
📣Management of refractory generalized myasthenia gravis with eculizumab during pregnancy and puerperium: a case report

Karaman et al.

@drugsincontext.bsky.social #immunology #neurology #myastheniagravis #pregnancy #pharmacology #MedSky #PharmSky

www.drugsincontext.com/management-o...
Management of refractory generalized myasthenia gravis with eculizumab during pregnancy and puerperium: a case report - Drugs in Context
This case report describes a successful pregnancy in a patient who received eculizumab for refractory generalized myasthenia gravis that was difficult to manage during the pre-pregnancy period.
www.drugsincontext.com
October 2, 2025 at 2:33 PM
drugsincontext.bsky.social
📣 In vitro antimicrobial activity of an oral spray combining 0.15% benzydamine hydrochloride and 0.5% cetylpyridinium chloride

Capezzone et al.

@drugsincontext.bsky.social #antimicrobials #respiratorytractinfections #invitro #MedSky #PharmSky

www.drugsincontext.com/in-vitro-ant...
In vitro antimicrobial activity of an oral spray combining 0.15% benzydamine hydrochloride and 0.5% cetylpyridinium chloride - Drugs in Context
This study evaluates the in vitro antimicrobial activity of a new oral spray formulation combining 0.15% benzydamine hydrochloride and 0.5% cetylpyridinium chloride. In addition modified vaccinia Anka...
www.drugsincontext.com
September 29, 2025 at 7:15 AM
drugsincontext.bsky.social
📣 Tezepelumab for early-onset severe allergic asthma with persistent airflow limitation and small airway dysfunction: a treatable traits approach

Menzella et al.

@drugsincontext.bsky.social #RespiratoryDisease #asthma #biologics #allergy
#MedSky #PharmSky

www.drugsincontext.com/tezepelumab-...
Tezepelumab for early-onset severe allergic asthma with persistent airflow limitation and small airway dysfunction: a treatable traits approach - Drugs in Context
This article describes the clinical and functional evolution of a young patient with severe early-onset allergic asthma with impaired respiratory function treated with the anti-thymic stromal lymphopo...
www.drugsincontext.com
September 26, 2025 at 8:29 AM
drugsincontext.bsky.social
📣 10 years of real-world data: long-term efficacy and safety of HyalOne® for hip osteoarthritis

Migliore et al.

www.drugsincontext.com/10-years-of-...

@drugsincontext.bsky.social

#Osteoarthritis #Orthopedics #HipOA #LongitudinalStudy #HyaluronicAcid #Rheumatology #MedSky #PharmSky
September 22, 2025 at 8:10 AM
drugsincontext.bsky.social
Nurses’ perceptions on the usability of the Hyrimoz® Sensoready® autoinjector device

Both et al.

www.drugsincontext.com/nurses-perce...

@drugsincontext.bsky.social

#nursing #gastroenterology #patientcare #usability #medicaldevices #PharmSky #MedSky
September 18, 2025 at 7:57 AM
drugsincontext.bsky.social
Treatment of vitiligo with topical ruxolitinib: a narrative review

Monteiro e Silva et al.

Review in @drugsincontext.bsky.social on topical ruxolitinib for non-segmental vitiligo.

#MedSky #dermatology #vitiligo #biologics #smallmoleculemedication #PharmSky

www.drugsincontext.com/treatment-of...
Treatment of vitiligo with topical ruxolitinib: a narrative review - Drugs in Context
This narrative study aims to review and synthesize the current evidence on the safety, efficacy and therapeutic impact of topical ruxolitinib cream in vitiligo.
www.drugsincontext.com
September 15, 2025 at 3:34 PM
drugsincontext.bsky.social
📣Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms

Dattola et al.

#drugsincontext #dermatology #psoriasis #PsoriaticArthritis #biologics #RealWorldEvidence #MedSky #PharmSky #DermSky

www.drugsincontext.com/real-world-a...
Real-world analysis of IL-23 inhibitors in patients with moderate-to-severe psoriasis and early musculoskeletal symptoms - Drugs in Context
This article aims to evaluate the effect of IL-23 inhibitors on clinical outcomes and progression of PsA in patients with moderate-to-severe psoriasis and early musculoskeletal involvement.
www.drugsincontext.com
September 9, 2025 at 7:31 AM
drugsincontext.bsky.social
Celebrating milestones and embracing innovation: the next chapter for Drugs in Context

www.drugsincontext.com/celebrating-...

@drugsincontext.bsky.social #Editorial #ImpactFactor #Publishing #OpenAccess #pharmacology #drugs #treatment #MedSky #PharmSky
Celebrating milestones and embracing innovation: the next chapter for Drugs in Context - Drugs in Context
The Senior Editors of Drugs in Context are excited to announce that the journal received its first Impact Factor of 2.8 in the 2025 Edition of Journal Citation Reports by Clarivate.
www.drugsincontext.com
August 29, 2025 at 1:52 PM
drugsincontext.bsky.social
New publication!

Dupilumab reduces patient-reported cough and improves quality of life in patients with severe eosinophilic #asthma with or without chronic rhinosinusitis with #nasalpolyps: a real-life prospective study

Lombardi et al.

#MedSky #PharmSky
www.drugsincontext.com/dupilumab-re...
August 26, 2025 at 3:11 PM